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Abstract
We previously reported the effectiveness of loxoprofen sodium (loxoprofen), a non-steroidal
anti-inflammatory drug, for patients with lower urinary tract symptoms (LUTS) complaining of
nocturia. In this study, we explored the mechanism of loxoprofen in the treatment of nocturia.
Fifty-six patients complaining of nocturia were enrolled. They took a single 60-mg tablet of
loxoprofen at bedtime for 14 days. The effects of this treatment were assessed by bladder diaries.
Nocturia improved (nocturia decreased ≥1 void/night) in 40 patients (71.4%). Nocturnal urine
volume was reduced in 31 of 40 (77.5%) without nocturnal single-void volume increase. Nocturnal
single-void volume increased in 4 of 40 (10.0%) without nocturnal urine volume reduction. Two of
40 (5.0%) demonstrated both nocturnal urine volume reduction and nocturnal single-void volume
increase. Three (7.5%) were exceptions to the above. In conclusion, the main mechanism of
loxoprofen is the reduction of nocturnal urine volume for the treatment of nocturia and the second
mechanism is the increased bladder capacity.
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ower urinary tract symptoms (LUTS) are a 
major health problem for elderly people.  
Nocturia,  a cause of insomnia and thus impaired qual-
ity of life,  is one of the main problems in LUTS along 
with urinary incontinence and diﬃculty in urination.  
Nocturia is not only a signiﬁcant bother to patients,  
but is associated with increases in morbidity,  risk of 
nighttime falls,  and mortality [1].
　 The etiology of nocturia is varied and complex in 
many patients.  However,  the pathophysiological basis 
for nocturia can be divided into 3 categories: (1) 
Excessive urine output,  (2) Sleep-related diﬃculties 
and (3) Urinary tract dysfunction [2].
　 We previously reported that loxoprofen sodium 
(loxoprofen),  a prodrug in the class of short-acting 
non-steroidal anti-inﬂammatory drugs (NSAIDs),  
reduces nocturia in patients with benign prostatic 
hyperplasia (BPH) and neurogenic bladder [3,  4].  
As reported in these papers,  nocturia improved or 
disappeared in 74.2ｵ and 80.6ｵ of the patients with 
BPH and neurogenic bladder,  respectively.  Al-Waili 
reported that indomethacin suppositories (a potent 
PGs synthesis inhibitor) reduced the frequency of 
nocturnal voiding and decreased the urine volume in 
enuresis [5ﾝ7].  Other papers have demonstrated that 
aspirin and diclofenac were also eﬀective for nocturia 
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[8,  9].  The main mechanism of NSAIDs for the 
treatment of nocturia is considered to be the reduction 
of nocturnal urine volume [5,  10,  11].  However,  we 
observed that nocturia improved in some patients on 
loxoprofen without reducing the nocturnal urine vol-
ume.
　 We prospectively investigated the mechanism of 
loxoprofen for nocturia in this study.
Materials and Methods
　 Between January 2003 and April 2005,  56 
patients with LUTS complaining of nocturia were 
enrolled.  Nocturia was conﬁrmed by bladder diary as 
one or more voids per night on average.  The risks and 
possible adverse eﬀects of loxoprofen were carefully 
explained to the patients prior to enrollment in the 
study,  and written informed consent was obtained.  
The patients took a 60-mg tablet of loxoprofen at 
bedtime for 14 days.  The patients were required to 
keep a bladder dairy.  They recorded all micturitions 
and the time of sleep and rising.  The diaries were kept 
before and during loxoprofen treatment.  The eﬀects 
of this treatment were assessed from the data in the 
bladder diaries.  The diﬀerences in data between the 
baseline and during treatment were investigated in 
terms of the frequency of voiding,  urine volume and 
single-void volume.  The average ratio of the nighttime 
urine volume was also compared.
　 All medications before loxoprofen treatment were 
continued during the loxoprofen treatment.  These 
included α1-blockers,  tricyclic antidepressants,  
anticholinergic medication and sleeping pills.  Before 
the treatment,  48 patients had been treated with 
α1-blockers,  18 patients with tricyclic antidepres-
sants (imipramine or amytriptyline),  10 patients with 
anticholinergic medication (propiverine or oxybutynin),  
and 7 patients with sleeping pills (zolpidem) for noc-
turia.  Twenty-seven patients had been treated with 
combination therapy.  Therefore,  none of the patients 
were on only loxoprofen during this study.  The 
patients had been on these medications for a minimum 
of 1 month prior to beginning the current study,  but 
were still having 1 or more nocturia episodes per 
night.  The improvement of nocturia was deﬁned as a 
decrease by at least 1.0 void/night on average.  
Adverse events were carefully reviewed by an inter-
view at clinic visits including serum creatinine (sCr) 
and blood urea nitrogen (BUN) abnormality.  Patients 
who had asthma,  gastrointestinal disorders,  renal 
dysfunction or allergies to NSAIDs were excluded.
　 For statistical analyses,  the Wilcoxon signed rank 
test was used to compare the data between before and 
during treatment in each group,  while Mann-Whitney 
U-tests were used for intergroup comparisons.  P＜
0.05 was considered signiﬁcant.  Values are reported 
as the mean ± standard deviation.
Results
　 Fifty-six (53 males and 3 females) patients with a 
mean age of 71.5 years (52ﾝ88) were enrolled in this 
study.  Nocturia improved (mean nocturia decreased by 
at least 1.0 void/night) or disappeared in 40 patients 
(38 males and 2 females) (71.4ｵ),  with a mean age of 
72.3 years (52ﾝ88).  The data from the bladder diaries 
of the 56 patients are shown in Table 1.  Total urine 
volume,  nocturnal urine volume,  and total number of 
nocturnal voids signiﬁcantly decreased during treat-
ment.  However,  nocturnal single voided volume did 
not show a signiﬁcant change (Table 1).  Nocturnal 
urine volume signiﬁcantly decreased in both the eﬀec-
tive and non-eﬀective groups.  However,  the nocturnal 
urine volume was reduced more signiﬁcantly in the 
eﬀective group than in the non-eﬀective group.  
Nocturnal single voided volume was signiﬁcantly 
reduced in the non-eﬀective group (Table 1).
　 We further analyzed the data of the 40 patients in 
the eﬀective group.  We classiﬁed them into 4 groups 
based on 2 factors: 1.  Nocturnal urine volume reduc-
tion (with or withoutｧ150 ml orｧ10ｵ reduction 
from baseline),  2.  Nocturnal single voided volume 
increase (ｧor＜150ｵ increase from baseline).  
Group A (Nocturnal urine volume reduction type) was 
deﬁned as a nocturnal urine volume reduction of more 
than 150 ml orｧ10ｵ reduction from the baseline 
with＜150ｵ nocturnal single voided volume increase.  
Group B (Nocturnal single voided volume increase 
type) was deﬁned as an increase of the nocturnal single 
voided volume by 150ｵ or more from the baseline 
without nocturnal urine volume reduction.  Group C 
(Mixed type) was deﬁned as an increase of the noctur-
nal single voided volume by 150ｵ or more from the 
baseline with nocturnal urine volume reduction.  Group 
D were exceptions to the above.
　 Thirty-one of 40 (77.5ｵ) were classiﬁed as group 
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A,  whose nocturnal urine volume and total nocturnal 
void signiﬁcantly decreased during loxoprofen treat-
ment.  However,  the nocturnal single voided volume 
did not show any signiﬁcant change (Table 2).  Four 
(10.0ｵ) were classiﬁed as group B.  Two (5.0ｵ) 
were classiﬁed as group C.   The rest 3 (7.5ｵ) were 
classiﬁed as group D.  In groups B,  C,  and D,  noc-
turnal single voided volume increased during the 
treatment (Table 2).  Table 3 shows the groups B,  C,  
and D cases.  Nocturnal single voided volume 
increased during treatment in these 9 patients (groups 
B,  C and D).  Even in group A,  nocturnal single 
voided volume was increased from 7 to 24ｵ (median 
11ｵ) in 9 of 31 patients (N. S. ) (Table 4).  
Altogether,  bladder capacity was increased in 18 of 
the 40 eﬀective patients (45.0ｵ) during the treatment.  
Bladder capacity was also increased from 6 to 18ｵ 
(median 15ｵ) in 5 of 16 non-eﬀective patients (31.3ｵ) 
during the treatment (Table 4).  A side eﬀect occurred 
in one patient (1.8ｵ),  who complained of gastric dis-
comfort.  sCr or BUN did not change in any of the 
patients.
Discussion
　 Loxoprofen is a relatively short half-life NSAID 
pro-drug and inhibits prostaglandin (PG) synthesis via 
the inhibition of non-selective cyclooxygenase (COX).  
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Table 1　 Nocturia and urine volume before and during the treatment by loxoprofen in 56 patients
No. voids / night Urine volume / night Single voided volume / night Urine volume / day
(mL) (%/day) (mL) (mL)
Baseline 2.8±1.1 776±256 43.4±10.5 226±86.5 1,811±523
During 1.5±0.9 523±230 32.6±11.4 223±76.4 1,668±569
P＊ ＜0.0001 ＜0.0001 ＜0.0001 NS 0.0013
Non-eﬀective group (n＝16)
Baseline 2.2±1.0 746±253 37.2±9.7 254±115 2,014±552
During 1.8±1.0 591±250 31.4±8.8 214±80.1 1,893±605
P* 0.0040 0.0009 0.0023 0.0494 NS
Eﬀective group (n＝40)
Baseline 3.0±1.1 788±260 45.9±9.9 215±70.9 1,730±495
During 1.8±0.8 508±220 33.1±12.4 226±75.6 1,578±260
P＊ ＜0.0001 ＜0.0001 ＜0.0001 NS 0.0042
P＊＊ ＜0.0001 　0.0193 　0.0013 0.0370 NS
P＊ Comparison between baseline and during treatment: Wilcoxon signed rank test;
P＊＊ Comparison between eﬀective (mean nocturia decreased by≧1.0 void/night) and non-eﬀective groups (mean nocturia decreased by＜1.0 void/
night) groups: Mann-Whitneyʼs U-test.
NS, not signiﬁcant.
Table 2　 Nocturia and urine volume before and during the treatment by loxoprofen in the 40 eﬀective patients
Group No. pts No. voids / night Urine volume / night Single voided volume / night Urine volume / day
(%) (mL) (%/day) (mL) (mL)
A 31 Baseline 2.9±1.1 827±254 47.0±9.7 230±69 1,760±438
(77.5%) During 1.2±0.8 472±219 30.6±11.2 220±73 1,542±483
P＊ ＜0.0001 ＜0.0001 ＜0.0001 NS 0.0004
B 4 Baseline 3.4±1.4 626±242 44.1±11.0 157±36 1,463±537
(10.0%) During 1.7±0.7 680±158 44.0±14.0 268±78 1,729±804
C 2 Baseline 3.3±1.8 838±392 33.1±5.8 172±24 2,468±746
(5.0%) During 1.9±1.2 714±330 31.0±17.0 284±15 2,387±274
D 3 Baseline 3.1±1.0 565±183 44.9±10.3 166±94 1,283±444
(7.5%) During 1.8±0.8 522±114 45.0±11.3 208±117 1,210±406
P＊ Comparison between baseline and during treatment: Wilcoxon signed rank test.
NS, not signiﬁcant.
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PGs have various eﬀects on the renal system,  vesical,  
urethral and sympathetic nervous systems,  and thus 
loxoprofen may also act on the same portions as PG 
synthesis inhibitors.  We previously reported that 
nocturia improved in 74ｵ of patients with BPH by 
loxoprofen [3].  That was the ﬁrst report demon-
strating the eﬀectiveness of loxoprofen for the treat-
ment of nocturia.  Saito et al.  subsequently reported 
the eﬀectiveness of loxoprofen for patients with noc-
turia [10].
　 Why is loxoprofen eﬀective in reducing nocturia? 
There are 4 possible sites where loxoprofen may act: 
1.  Reducing urine volume produced in the kidney,  2. 
Decreasing detrusor muscle tone,  3.  Aﬀecting urinary 
sensation at the bladder,  4.  Aﬀecting sleep in the 
brain.  It is known that PGs contribute to urine pro-
duction in the kidney.  They inhibit sodium tubular 
reabsorption and anti-diuretic hormone (ADH),  
decrease aldosterone secretion and cause glomerular 
vasodilation,  natriuresis and diuresis [12].  
Therefore,  NSAIDs suppress urine production by 
decreasing glomerular blood ﬂow,  particularly in the 
impaired kidney [13].  Several reports have suggested 
that the main mechanism of this eﬀect is to decrease 
urine production during the night [9ﾝ11].
　 In our previous study,  however,  we found that 
there were some patients whose nocturia improved 
with loxoprofen even with increased nocturnal urine 
volume [4].  This interesting ﬁnding led us to investi-
gate the mechanism of loxoprofen for the treatment of 
nocturia.  Actually,  several studies have demonstrated 
the clinical eﬃcacy of PG synthesis inhibitors on 
detrusor overactivity [14ﾝ16].  It has also been sug-
gested that an important physiologic role of PGs on 
bladder function might be sensitization of the sensory 
nerves.  PGs may indirectly aﬀect bladder activity via 
eﬀects on neurotransmission as neurotransmitters/
modulators [17ﾝ19].  Accordingly,  it is suspected 
that loxoprofen might improve nocturia by increasing 
the threshold of urinary sensation in the central ner-
vous system (CNS) via the suppression of aﬀerent 
and/or eﬀerent nerve pathways.  The levels of PGD2 
and PGE2 in the brain have been shown to be related 
to the sleepﾝwake cycle [19,  20].  It is widely known 
that NSAIDs suppositories provide patients with good 
sleep as a secondary eﬀect.
　 Our data demonstrated that loxoprofen signiﬁ-
cantly reduced nocturia and nocturnal urine volume.  
Nocturnal urine volume in particular was reduced by 
a signiﬁcantly greater degree in the eﬀective group 
than in the non-eﬀective group.  However,  there were 
no signiﬁcant diﬀerences in nocturnal single voided 
urine volume during the treatment in 56 patients 
(Table 1).  We then focused on the data of the 40 
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Table 3　 Nocturia and urine volume before and during the treatment by loxoprofen in each patient of groups B, C, and D
Patient No. voids / night Urine volume / night Single voided volume / night Urine volume / day
(Age) (mL) (%/day) mean (range) (mL) (mL)
B1 Baseline 5.0  775 45 138 (100ﾝ250) 1,713
(71) During 2.7  716 42 208 (175ﾝ250) 1,697
B2 Baseline 2.0  320 47 115 ( 70ﾝ140)  685
(74) During 1.0  450 61 200 (190ﾝ220)  740
B3 Baseline 2.5  550 29 186 ( 80ﾝ350) 1,895
(65) During 1.0  740 27 360 (330ﾝ380) 2,710
B4 Baseline 4.0  860 55 188 ( 80ﾝ300) 1,560
(82) During 2.0  810 46 305 (280ﾝ310) 1,770
C1 Baseline 2.0  560 29 155 (110ﾝ200) 1,940
(82) During 1.0  480 19 280 (250ﾝ310) 2,580
C2 Baseline 4.5 1,115 37 189 (100ﾝ310) 2,995
(74) During 2.7  947 43 287 (180ﾝ350) 2,193
D1 Baseline 2.0  770 43 275 (200ﾝ340) 1,773
(62) During 1.0  643 39 343 (260ﾝ390) 1,660
D2 Baseline 3.3  417 36 117 ( 50ﾝ250) 1,167
(88) During 2.0  417 38 150 (100ﾝ250) 1,100
D3 Baseline 4.0  509 56 107 ( 50ﾝ150)  908
(85) During 2.5  505 58 132 ( 80ﾝ240)  870
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eﬀective patients.  Nocturia was improved mainly due 
to an increase of the nocturnal single voided volume in 
9/40 (22.5ｵ) (groups B,  C and D) during loxoprofen 
treatment.  31/40 (77.5ｵ) demonstrated the reduction 
of nocturnal urine volume by more than 150ml or 10ｵ 
from the baseline (group A).  NSAIDs mainly contrib-
ute to suppression of urine production in the kidney by 
decreasing glomerular blood ﬂow.  The reduction of 
urine volume is a major mechanism of loxoprofen,  
because the nocturnal urine volume reduced signiﬁ-
cantly,  and 77.5ｵ of eﬀective patients demonstrated 
reduction of the nocturnal urine volume during treat-
ment.  However,  4/40 (10.0ｵ) demonstrated increased 
nocturnal single voided volume during loxoprofen 
administration without a signiﬁcant change of the 
nocturnal urine volume (Group B,  Tables 2,  3).  
2/40 (5ｵ) demonstrated a reduction of the nocturnal 
urine volume and an increase of the nocturnal single 
voided volume (Group C,  Tables 2,  3).  In 3 patients 
(7.5ｵ),  nocturia was improved despite only a small 
change of the nocturnal urine volume and/or nocturnal 
single voided urine volume (Group D,  Tables 2,  3),  
although it is diﬃcult to specify the real mechanism 
for this improvement.  In addition,  the nocturnal single 
voided volume was increased from 7 to 24ｵ (median 
11ｵ) in 9 of 31 patients in group A,  although the 
increases were small (Table 4).  Altogether,  bladder 
capacity was increased in 18 of 40 eﬀective patients 
(45.0ｵ) by loxoprofen.  Even in non-eﬀective patients,  
bladder capacity was increased from 6 to 18ｵ 
(median 15ｵ) in 5 of 16 non-eﬀective patients 
(31.3ｵ) (N. S. ).  Therefore,  it seems that an increase 
in bladder capacity is the second mechanism of loxo-
profen.
　 Adverse events of loxoprofen are less frequent 
than other NSAIDs because loxoprofen is a prodrug 
of a short-acting NSAID.  However,  it should be kept 
in mind that many patients with nocturia are elderly 
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Table 4　 Nocturia, urine volume, and nocturnal single voided volume before and during the treatment by loxoprofen in each patient who 
demonstrated an increase of nocturnal single voided volume during treatment of group A and the non-eﬀective group (NE)
Patient No.  voids / night Urine volume / night Single voided volume / night Urine volume / day
(Age) (mL) (%/day) mean (mL) (%/pre) (mL)
A6 Baseline 1.0  233 31 125  750
(78m) During 0.0  155 19 155 (124)  830
A8 Baseline 6.0 1,217 46 174 2,630
(67m) During 3.8  975 34 206 (118) 2,900
A12 Baseline 2.7 1,175 47 318 2,508
(85f) During 1.2  850 40 350 (110) 2,133
A15 Baseline 2.5  810 47 233 1,735
(72m) During 1.0  450 31 250 (107) 1,455
A19 Baseline 2.8 1,103 52 298 2,130
(72m) During 1.0  770 39 331 (111) 1,979
A20 Baseline 1.5  600 37 217 2,995
(80f) During 0.0  250 18 250 (115) 1,375
A23 Baseline 2.0  945 42 360 2,265
(57m) During 1.0  650 29 400 (111) 2,280
A29 Baseline 3.5  783 55 176 1,428
(75m) During 1.0  400 43 203 (115)  943
A31 Baseline 5.0 1,340 52 221 2,595
(62m) During 2.0  735 38 255 (115) 1,920
NE42 Baseline 1.3  240 23 102 1,023
(80m) During 1.0  207 23 117 (115)  893
NE45 Baseline 1.0  497 20 170 2,453
(66f) During 0.3  428 19 200 (118) 2,223
NE48 Baseline 1.4  814 40 393 2,042
(63m) During 1.0  730 33 430 (109) 2,180
NE50 Baseline 3.5  893 50 204 1,793
(76m) During 2.7  787 40 234 (115) 1,980
NE56 Baseline 2.3  665 38 218 1,770
(62m) During 1.8  635 39 230 (106) 1,620
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and may have low thresholds for the development of 
gastrointestinal ulcers and renal dysfunction,  2 well-
known adverse events associated with the long-term 
administration of NSAIDs [21].
　 The limitation of this study was the lack of a con-
trol group.  However,  this is the ﬁrst report elucidat-
ing the mechanism of loxoprofen for the treatment of 
nocturia.  Before this treatment,  all of our patients 
were on some medications for nocturia,  including 
α1-blockers,  anticholinergic medication,  or sleeping 
pills,  suggesting they had refractory nocturia,  and 
they continued their medications during the study.  Our 
data demonstrated that loxoprofen can increase the 
bladder capacity of patients with refractory nocturia.  
There have been no reports clearly demonstrating the 
increased bladder capacity with NSAIDs before.  
Further investigation is needed to evaluate the eﬀects 
of PG synthesis inhibitors in the treatment of nocturia 
and detrusor overactivity.  In conclusion,  loxoprofen 
is eﬀective for the treatment of nocturia.  The main 
mechanism of loxoprofen was the reduction of noctur-
nal urine volume.  The second mechanism is the 
increased bladder capacity.  Our results suggest that 
loxoprofen has an eﬀect on the detrusor muscle or 
urinary sensation at the bladder and/or CNS.
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